Plasma choline-containing phospholipids: potential biomarkers for colorectal cancer progression
Plasma choline-containing phospholipids: potential biomarkers for colorectal cancer progression
复制标题
血浆含胆碱磷脂：结直肠癌进展的潜在生物标志物
DOI：
10.1007/s11306-012-0439-z
复制
发表时间：
2013-02-01
期刊：
影响因子：
3.6
通讯作者：
Zhang, Junjie
中科院分区：
文献类型：
--
作者：
Li, Song;Guo, Bin;Zhang, Junjie
结直肠癌(CRC)被认为是通过腺瘤-癌序列进行的。腺瘤向癌的转变是早期发现和干预结直肠癌的重要窗口。本研究收集了结直肠癌患者(n=120)、腺瘤性息肉(n=120)和健康对照组(n=120)的血浆样本。用液相色谱-串联质谱仪分析血浆磷脂水平。结果发现，血浆主要溶血磷脂酰胆碱(LPC)水平从健康对照组、急性胰腺炎(AP)到结直肠癌患者逐渐降低。以总饱和LPC、18：2 LPC和鞘氨醇磷脂酰胆碱(SPC)为指标，诊断结直肠癌的敏感性和特异性分别为88.3%和80%。以总饱和LPCS、20：4 LPC和鞘磷脂(SM)为标记物的AP诊断模型的灵敏度和特异度分别为89%和80%。以SM、SPC和饱和LPCS为标记物，建立了区分结直肠癌和急性胰腺炎的模型，其敏感度和特异度分别为90%和92.5%。这些数据表明，含有胆碱的磷脂水平是区分健康对照、AP和CRC的潜在生物标志物，暗示它们在CRC和/或AP-CRC进展检测中的临床应用。
Colorectal cancer (CRC) is believed to progress through the adenoma-carcinoma sequence. The adenoma-carcinoma transition is an important window for early detection and intervention of CRC. In the present study, plasma samples from patients with CRC (n = 120), patients with adenomatous polyps (AP) (n = 120), and healthy controls (n = 120) were collected. Plasma phospholipid levels were analyzed with liquid chromatography-tandem mass spectrometry. It was found that the plasma levels of major lysophosphatidylcholine (LPC) species were gradationally decreased from healthy controls, AP to CRC subjects. A formula including total saturated LPCs, 18:2 LPC and sphingosylphosphorylcholine (SPC) yielded a sensitivity and specificity of 88.3 and 80 % for separating CRC from healthy controls. An optimized model with total saturated LPCs, 20:4 LPC and sphingomyelins (SM) as markers yielded a sensitivity and specificity of 89 and 80 % for separating AP from the healthy controls. Moreover, with SM, SPC and saturated LPCs as markers, a model was made to separate CRC from AP with the sensitivity and specificity of 90 and 92.5 %, respectively. These data indicate that the plasma choline-containing phospholipid levels represent potential biomarkers to distinguish between healthy controls, AP and CRC cases, implying their clinical usage in CRC and/or AP-CRC progression detection.